Form 4: NeuroMetrix Director Receives Restricted Stock Units
SEC Form 4 Filing
Bradley M. Fluegel, a director of NeuroMetrix, Inc., was granted 13,730 restricted stock units on May 22, 2024, vesting on the earlier of the 2025 annual meeting or a change in control.
Summary
- On May 22, 2024, Bradley M. Fluegel, a director of NeuroMetrix, Inc., received 13,730 restricted stock units.
- The restricted stock units will vest 100% on the earlier of the date of the 2025 annual meeting of stockholders or a change in control of NeuroMetrix.
- Vesting is contingent upon Mr. Fluegel's continued service on the Board of Directors.
- The price on the Nasdaq market on April 30, 2024, was $4.37.
Sentiment
Score: 7
Explanation: The document reflects a routine grant of stock units, which is generally neutral to slightly positive as it aligns director interests with shareholders.
Positives
- The grant of restricted stock units aligns the director's interests with those of the shareholders.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance, only the vesting schedule of the restricted stock units.
Industry Context
This is a standard practice for compensating board members in publicly traded companies, aligning their interests with shareholders through equity-based compensation.
Comparison to Industry Standards
- Granting restricted stock units to directors is a common practice among publicly traded companies to incentivize performance and align interests with shareholders.
- The vesting schedule, contingent on continued service and potentially accelerated by a change in control, is also typical.
- Comparable companies in the medical device industry, such as Masimo or Insulet, often use similar equity compensation strategies for their board members.
Stakeholder Impact
- Shareholders may view this as a positive sign, as it aligns the director's interests with the company's long-term success.
- Employees are unlikely to be directly impacted by this transaction.
Key Dates
| Date | Description |
|---|---|
| 04/30/2024 | Pricing on the Nasdaq market was $4.37 |
| 05/22/2024 | Reporting person was granted 13,730 restricted stock units |
| 04/29/2025 | Date the restricted stock units are exercisable |
| 04/29/2025 | Expiration date of the restricted stock units |
Keywords
NeuroMetrix, Director, Restricted Stock Units, NURO, Vesting, Beneficial Ownership, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.